53results about How to "Therapeutic effect" patented technology

A process for preparing divalproex sodium tablets is provided. The process comprises preparing a neutralized divalproex sodium solution by combining divalproex sodium, having a sodium valproate and a valproic acid moiety, with an aqueous solvent and a base, e.g., sodium hydroxide, the base being in sufficient amount to ensure neutralization of the valproic acid moiety of the divalproex sodium. The neutralized divalproex sodium solution is sprayed onto a pharmaceutically acceptable carrier, and processed to obtain divalproex sodium tablets.

Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing αv integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing αv integrins in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tissue experiencing angiogenesis or to cells or tissue expressing αv integrins.

Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity at blood-brain, blood-CSF and placental-maternal barriers to increase the efflux of drugs and other compounds from physiological compartments, including central nervous system and fetal compartments.

The invention relates to compositions, kits, and methods for cancer therapy using recombinant poxviruses encoding a tumor-associated antigen in combination with antagonists or agonists of immune checkpoint inhibitors.

This application describes compositions of receptor inhibitors, including antipsychotic agents, for example haloperidol, and methods of use for alleviating clinical depression, improving cognition and/or treating other syndromes, conditions or diseases for which anti-depressant agents are prescribed. Furthermore, this application describes compositions and methods to induce supersensitivity in dopamine D2 and other receptors involved in depression and/or cognition as a means of alleviating clinical depression or improving cognition.

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.

This invention provides a method and a system for preventing charring at a laser beam emitting site during treatment or diagnosis using a laser catheter for applying a laser beam. The method is intended to control laser beam irradiation of an apparatus equipped with a laser catheter comprising a laser beam transmission means and a laser beam emitting site used for diagnosis or treatment with the irradiation of the inside of a blood vessel or heart cavity with a laser beam. The method for controlling laser beam irradiation is intended to prevent blood charring at a laser emission site of an apparatus equipped with a laser catheter, and the method comprises a step of controlling a laser beam output in accordance with temporal changes in the intensity of the diffuse reflected light beam by erythrocytes applied to the inside of a blood vessel or heart cavity.

The invention provides polypeptide microparticles having control release features, particular methods for the preparation of such microparticles, and drug delivery systems that include polypeptide microparticles.

The present invention provides purified protease inhibitors derived from microorganisms alone or in combination with bacteriocins and/or antibodies. The protease inhibitors may also be expressed by microbiome or probiotic microorganisms alone or in combination with bacteriocins and/or antibodies. The invention also provides methods and compositions for improving the expression of endogenous or heterologous protease inhibitors alone or in combination with bacteriocins and/or antibodies. The invention is useful for treating a variety of inflammatory disorders including acne, psoriasis, eczema, atopic dermatitis and inflammatory bowel disease.

In some embodiments, systems and methods can include a wearable device with an electrically conductive skin interface that excites the underlying nerves from a transcutaneous surface stimulator. The device may be sized for a range of user sizes with stimulation electrodes positioned to target the appropriate nerves, such as the saphenous and/or tibial nerves. The stimulation could include burst stimulation, and involve receiving an input relating to autonomic nervous system activity of the patient, and modifying at least one brain or spinal cord autonomic feedback loop relating to bladder function based on the input to balance parasympathetic and sympathetic nervous system activity of the patient.

The invention relates to a focusing ultrasonic cavitation treatment instrument which is used for treating tumor, thrombolysis, ischemic myocardium and disease of prostate based on the cavitation effect of the ultrasonic contrast agent microvesicle. The focusing ultrasonic cavitation treatment instrument comprises a main control machine, two combined treatment probes, and a B ultrasonic machine with an ultrasonic focusing ultrasonic cavitation treatment instrument function. The focusing ultrasonic cavitation treatment instrument is mainly used for the partial area of the focus, and carries out non-invasive treatment on the tumor based on the cavitation effect of the microvesicle. The microvesicle can greatly improve the cavitation effect, so that the ultrasonic focusing positioning radiation with low power can be precisely carried out in the partial area of the focus, and the cavitation effect of the microvesicle within the vessel just can be activated within the partial area, and the capillaries in the tumor can be subject to embolism and damage, so as to achieve the purpose of 'starving' the tumor. The threshold for generating the cavitation is not met by the ultrasonic energy at the periphery of the focusing area, so that the cavitation effect is not generated, so that the path where the ultrasonic wave passes or the ambient tissue can not be damaged; and the functions of the common tissue and organs are protected.

The present invention provides a novel therapeutic agent for a lifestyle-related disease or cibophobia, which is superior in controlling food intake, and a screening method therefor. More specifically, a therapeutic agent for a lifestyle-related disease containing, as an active ingredient, a substance that suppresses expression or function of GPCR that expresses in hypothalamus, clone 901, a therapeutic agent for cibophobia containing, as an active ingredient, a substance that enhances expression or function of the clone, a screening system consisting of a series of coexpression systems of clone 901 and various G proteins, and a screening method for a substance having a therapeutic activity against a lifestyle-related disease or cibophobia, which includes use of the screening system, are provided.

The present invention provides an herbal pharmaceutical compositions comprising the root of scutellaria, the rhizome of coptis, the root and rhizome of rhubarb, and the dry powders of the root of ginseng (or American ginseng) or the rhizome of ginger. The herbal pharmaceutical compositions are effective in preventing patients from developing or treating patients with cardiovascular diseases, which include, but are not limited to, hypertension, coronary heart disease, cerebrovascular disease, peripheral vascular disease, heart failure, rheumatic heart disease, congenital heart disease, and cardiomyopathies. The present invention also provides methods for preparing and using the herbal pharmaceutical compositions.

New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.

A composition for photodynamic therapy or diagnosis includes a photosensitizer-metallic nanosheet complex. In a case of using a folic acid-loaded metallic nanosheet, a poorly-soluble photosensitizer may be effectively loaded, thus to increase solubility and the photosensitizer may not be degraded in blood during in vivo administration but may maintain stability, thereby inhibiting imprudent release of the photosensitizer. Further, the nanosheet entered into the cancer cells may be substantially completely degraded by glutathione (GSH) present at a high concentration in the cancer cells. Therefore, it is expected that using the photosensitizer-metallic nanosheet complex may drastically reduce a dose of an anticancer agent while having little side effects and may enable effective treatment, thereby achieving a novel concept in anticancer therapeutic effects.

An erythrocyte de-aggregation system includes a band, including a strap and housing securing an iron-cored, micro-coil to an appendage, such as a wrist, of a subject to apply a PEMF into a target vessel in the vascular system of the subject. Typically, all of the blood circulates about the body within a matter of a few minutes, some within seconds, thus treating the entire bloodstream over time. The portable PEMF system intensifies both the concentration of electromagnetic flux per unit area, as well as the depth of penetration into the body. The portable PEMF systems relies on the body's circulatory system to eventually pass the body's entire volume of blood past it over a period of time.

An electric therapy apparatus 1 of the present invention includes: a voltage generating unit 14 for generating a predetermined voltage; a control unit 2 for varying the voltage generated by the voltage generating unit 14 and the output time of the voltage according to a 1/f fluctuation cycle; and potential therapy conductor terminals 27, 28 for applying the potential from the voltage generating unit 14 to a therapy object, and as a result, the therapy object is prevented from getting acclimatized to stimulation by a constant potential, thereby allowing the human body to be imparted with a relaxing feeling, while sustaining the therapeutic effect of the apparatus.

A flexible magnetic pad is provided with constantly alternating polarity zones which therapeutically affect blood vessels to increase blood flow, irrespective of the orientation of any blood vessel with respect to the pad, the polarity zones being arranged in an alternating pattern throughout the pad.

The invention relates to use of compounds which inhibit VAP-1/SSAO activity for the treatment of muscular dystrophy.

The present invention relates to a biphenyl derivative and use thereof, and the biphenyl derivative has a structure represented by the formula (I) as defined in the specification. The use refers the use of the biphenyl derivative or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising the biphenyl derivative or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for the treatment and/or prevention of ischemic stroke.

The present invention relates to a prophylactic and/or therapeutic agent for an allergic disease which contains a compound having an agonistic activity to EP3 receptor that is one of the prostaglandin E2 receptor subtypes. More specifically, a compound having an agonistic activity to EP3 receptor is effective in therapy of an allergic respiratory disease such as bronchial asthma, pediatric asthma, allergic asthma, or atopic asthma, and a selective agonistic compound can be expected to induce a more remarkable therapeutic effect.

The invention discloses a medicine for treating rhinitis, belonging to the technical fields of Chinese herbal medicinal preparations and applications of the Chinese herbal medicinal preparations. The medicine adopts the following medicinal materials for external application: flos magnoliae liliflorae, cocklebur fruits, radix angelicae, herba asari, ramulus cinnamomi, garlic bulbs, herba centipedae and borneol; the medicine adopts the following medicinal materials for oral administration: honeysuckle flowers, flos chrysanthemi indici, caulis luffae, herba rhodiolae sacrae, radix acanthopanacis semticosi, radix angelicae sinensis, fructus xanthii, radix angelicae, flos magnoliae officinalis, dandelion, flos carthami, and herba violae. The medicine adopting the prescription is refined and powerful, is simple, and is strong in practicability; after the medicine adopting the prescription is used for treating rhinitis, the relapse of rhinitis seldom occurs, and no side effects exist; the basic purpose of the medicine is to promote the blood circulation and replenish the blood, and improve the body immunity, the external warming the middle warmer and the internal dispelling wind and calming the liver are achieved together, so that the purpose of treating rhinitis is achieved.

A method of treating a central nervous system disease, the method including administering an agent including a therapeutically effective amount of vitamin B₁₂ to a patient with a central nervous system disease to treat the central nervous system disease. This disclosure also relates to a method of promoting M2 macrophage/microglia induction, inhibiting M1 macrophage/microglia induction, and/or reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia in a patient in need thereof, the method including administering an agent including a therapeutically effective amount of vitamin B₁₂ to the patient to promote M2 macrophage/microglia induction, inhibit M1 macrophage/microglia induction, and/or reduce the ratio of M1 macrophage/microglia to M2 macrophage/microglia. This disclosure also relates to a pharmaceutical product including vitamin B₁₂.

The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.

A neuromodulation system and method with feedback optimized electrical field generation for stimulating target tissue of a patient to treat neurological and non-neurological conditions. The system generally includes implantable electrodes, implantable sensors, an implantable or external electrical signal generator, and an implantable or external controller. The controller controls the electrical signal generator to generate electrical noise stimulation signals that are delivered to the target tissue via the electrodes and that produce an optimized electric field having maximized voltage with low current density. The sensors produce temperature and impedance data for the target tissue and the controller automatically responds to values of the sensor data that indicate potential damage to the target tissue to reduce the strength of the electric field.